Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2014

Open Access 01-12-2014 | Research article

Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia

Authors: Eleni Jelastopulu, Evangelia Giourou, Giorgos Merekoulias, Angeliki Mestousi, Eleftherios Moratis, Evangelos C Alexopoulos

Published in: BMC Psychiatry | Issue 1/2014

Login to get access

Abstract

Background

Psychosocial dysfunction is one of schizophrenia’s core features, often leading to a deprecation of independent living and significant failure to maintain a competent quality of life. Cognitive and occupational performance as well as psychosocial functioning is moreover recognized as determinants of treatment response. Therefore, the elaboration of measures regarding social performance besides scales that assess psychopathology is essential. The Personal and Social Performance (PSP) scale has been found to be as much valid as reliable for assessing social functioning in the acute and stable stage of schizophrenia. The aim of this study was to estimate the correlation between the PSP and Positive and Negative Syndrome Scale (PANSS) (convergent validity) in patients with schizophrenia during routine clinical practice.

Methods

A longitudinal study with a six-month follow-up is presented. Correlation between the PSP scale and the Positive and Negative Syndrome Scale (PANSS) was conducted in a Greek sample of 2010 patients with schizophrenia in outpatient setting in two successive visits. PANSS and PSP scales were used for the assessment of psychopathological symptoms and social and personal functioning.

Results

The PSP subscales scores were well correlated with each other with Spearman correlation coefficients (r) ranging from 0.56 to 0.76 on both visits in three out of the four main areas, whereas in the category of “disturbing and aggressive behavior” the correlations were lower but still significant. Furthermore, total PSP score showed high association to PANSS total score in the first (r = -0.59) as well as in the second visit (r = -0.50). Regression analysis showed that one point decrease of PANSS’s total score is associated with a 0.42 points increase on the PSP scale. PSP and PANSS scales exhibited high convergent validity.

Conclusions

The PSP could provide additional valuable information in the assessment of schizophrenia related social functioning and treatment response.
Appendix
Available only for authorised users
Literature
1.
Bottlender R, Strauss A, Moller HJ: Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission. Schizophr Res. 2010, 116: 9-15. 10.1016/j.schres.2009.10.008.CrossRefPubMed
2.
Hafner H, Loffler W, Maurer K, Hambrecht M, An der Heiden W: Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand. 1999, 100: 105-118. 10.1111/j.1600-0447.1999.tb10831.x.CrossRefPubMed
3.
Stanghellini G, Ballerini M: Dis-sociality: the phenomenological approach to social dysfunction in schizophrenia. World Psychiatry. 2002, 1: 102-106.PubMedPubMedCentral
4.
Association AP: Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington DC: American Psychiatric Association
5.
Burns T, Patrick D: Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand. 2007, 116: 403-418. 10.1111/j.1600-0447.2007.01108.x.CrossRefPubMed
6.
Brune M, Schaub D, Juckel G, Langdon R: Social skills and behavioral problems in schizophrenia: the role of mental state attribution, neurocognition and clinical symptomatology. Psychiatry Res. 2011, 190: 9-17. 10.1016/j.psychres.2010.03.015.CrossRefPubMed
7.
Corcoran CM, Kimhy D, Parrilla-Escobar MA, Cressman VL, Stanford AD, Thompson J, David SB, Crumbley A, Schobel S, Moore H, Malaspina D: The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis. Psychol Med. 2011, 41: 251-261. 10.1017/S0033291710000802.CrossRefPubMed
8.
Smith TE, Hull JW, Huppert JD, Silverstein SM: Recovery from psychosis in schizophrenia and schizoaffective disorder: symptoms and neurocognitive rate-limiters for the development of social behavior skills. Schizophr Res. 2002, 55: 229-237. 10.1016/S0920-9964(01)00231-6.CrossRefPubMed
9.
Weinberg D, Shahar G, Davidson L, McGlashan TH, Fennig S: Longitudinal associations between negative symptoms and social functioning in schizophrenia: the moderating role of employment status and setting. Psychiatry. 2009, 72: 370-381.CrossRefPubMed
10.
Rocca P, Montemagni C, Castagna F, Giugiario M, Scalese M, Bogetto F: Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009, 33: 373-379. 10.1016/j.pnpbp.2009.01.002.CrossRefPubMed
11.
Brune M: Emotion recognition, ‘theory of mind’, and social behavior in schizophrenia. Psychiatry Res. 2005, 133: 135-147. 10.1016/j.psychres.2004.10.007.CrossRefPubMed
12.
Stefanopoulou E, Lafuente AR, Saez Fonseca JA, Huxley A: Insight, global functioning and psychopathology amongst in-patient clients with schizophrenia. Psychiatr Q. 2009, 80: 155-165. 10.1007/s11126-009-9103-9.CrossRefPubMed
13.
MacEwan TH, Athawes RW: The Nithsdale Schizophrenia Surveys. XV. Social adjustment in schizophrenia: associations with gender, symptoms and childhood antecedents. Acta Psychiatr Scand. 1997, 95: 254-258. 10.1111/j.1600-0447.1997.tb09628.x.CrossRefPubMed
14.
Rocca P, Pulvirenti L, Montemagni C, Rasetti R, Rocca G, Bogetto F: Basic symptoms in stable schizophrenia: relations with functioning and quality of life. Clin Neuropsychiatry. 2010, 7: 100-110.
15.
Karow A, Naber D: Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl). 2002, 162: 3-10. 10.1007/s00213-002-1052-z.CrossRef
16.
Juckel G, Morosini PL: The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry. 2008, 21: 630-639. 10.1097/YCO.0b013e328314e144.CrossRefPubMed
17.
Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000, 101: 323-329.PubMed
18.
Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D, Adriaenssen I: Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin. 2009, 25: 325-338. 10.1185/03007990802611919.CrossRefPubMed
19.
Juckel G, Schaub D, Fuchs N, Naumann U, Uhl I, Witthaus H, Hargarter L, Bierhoff HW, Brune M: Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophr Res. 2008, 104: 287-293. 10.1016/j.schres.2008.04.037.CrossRefPubMed
20.
Nasrallah H, Morosini P, Gagnon DD: Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008, 161: 213-224. 10.1016/j.psychres.2007.11.012.CrossRefPubMed
21.
Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007, 90: 147-161. 10.1016/j.schres.2006.09.012.CrossRefPubMed
22.
Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A: Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007, 62: 1363-1370. 10.1016/j.biopsych.2007.01.017.CrossRefPubMed
23.
Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M: Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007, 93: 117-130. 10.1016/j.schres.2007.03.003.CrossRefPubMed
24.
Ginsberg DL, Schooler NR, Buckley PF, Harvey PD, Weiden PJ: Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning. CNS Spectr. 2005, 10: 1-13. discussion 14–15PubMed
25.
Franz M: Possibilities and limitations of the use of quality of life as outcome-indicator in schizophrenic patients. Psychiatr Prax. 2006, 33: 317-322. 10.1055/s-2006-940194.CrossRefPubMed
26.
Angermeyer MC, Holzinger A, Matschinger H: Quality of life–what it means to me… Results of a survey among schizophrenic patients. Psychiatr Prax. 1999, 26: 56-60.PubMed
27.
Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13: 261-276. 10.1093/schbul/13.2.261.CrossRefPubMed
28.
Lykouras E, Botsis A, Oulis P: The Positive and Negative Syndrome Scale (PANSS) [in Greek]. 1994, Tsiveriotis Ed: Athens, Greece
29.
Apiquian R, Elena Ulloa R, Herrera-Estrella M, Moreno-Gomez A, Erosa S, Contreras V, Nicolini H: Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. Schizophr Res. 2009, 112: 181-186. 10.1016/j.schres.2009.03.028.CrossRefPubMed
30.
Fleischhacker WW, Kemmler G: The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology. 2007, 32: 2435-2436. 10.1038/sj.npp.1301391.CrossRefPubMed
31.
Eack SM, Newhill CE: Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007, 33: 1225-1237. 10.1093/schbul/sbl071.CrossRefPubMedPubMedCentral
32.
Woon PS, Chia MY, Chan WY, Sim K: Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34: 463-468. 10.1016/j.pnpbp.2010.01.014.CrossRefPubMed
33.
Rocca P, Giugiario M, Montemagni C, Rigazzi C, Rocca G, Bogetto F: Quality of life and psychopathology during the course of schizophrenia. Compr Psychiatry. 2009, 50: 542-548. 10.1016/j.comppsych.2008.12.002.CrossRefPubMed
34.
Tianmei S, Liang S, Yun’ai S, Chenghua T, Jun Y, Jia C, Xueni L, Qi L, Yantao M, Weihua Z, Hongyan Z: The Chinese version of the Personal and Social Performance Scale (PSP): validity and reliability. Psychiatry Res. 2011, 185: 275-279. 10.1016/j.psychres.2010.05.001.CrossRefPubMed
35.
Lindenmayer JP, Bernstein-Hyman R, Grochowski S: A new five factor model of schizophrenia. Psychiatr Q. 1994, 65: 299-322. 10.1007/BF02354306.CrossRefPubMed
36.
Lancon C, Auquier P, Nayt G, Reine G: Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res. 2000, 42: 231-239. 10.1016/S0920-9964(99)00129-2.CrossRefPubMed
37.
Hough D, Nuamah IF, Lim P, Sampson A, Gagnon DD, Rothman M: Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis. J Clin Psychopharmacol. 2009, 29: 496-497. 10.1097/JCP.0b013e3181b5f40b.CrossRefPubMed
Metadata
Title
Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia
Authors
Eleni Jelastopulu
Evangelia Giourou
Giorgos Merekoulias
Angeliki Mestousi
Eleftherios Moratis
Evangelos C Alexopoulos
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2014
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-14-197

Other articles of this Issue 1/2014

BMC Psychiatry 1/2014 Go to the issue

Study protocol

A cross-sectional survey of the mental health needs of refugees and asylum seekers attending a refugee health clinic: a study protocol for using research to inform local service delivery

Research article

The relationship between acculturation strategies and depressive and anxiety disorders in Turkish migrants in the Netherlands

Research article

A systematic review and meta-analysis of randomised controlled trials of peer support for people with severe mental illness

Study protocol

Effectiveness and cost-effectiveness of a guideline-based stepped care model for patients with depression: study protocol of a cluster-randomized controlled trial in routine care

Research article

The BDNFp.Val66Met polymorphism, childhood trauma, and brain volumes in adolescents with alcohol abuse

Study protocol

Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study